ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company focused on developing differentiated medicines to address unmet medical needs in patients with cancers, particularly non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The company serves patients with locally advanced or metastatic EGFRm NSCLC, targeting uncommon mutations such as exon 20 insertions and P-loop and alpha-c-helix compressing (PACC) mutations.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.